0000899243-15-001327.txt : 20150716 0000899243-15-001327.hdr.sgml : 20150716 20150716173551 ACCESSION NUMBER: 0000899243-15-001327 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150714 FILED AS OF DATE: 20150716 DATE AS OF CHANGE: 20150716 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDENBERG DAVID M CENTRAL INDEX KEY: 0001029578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 15992191 MAIL ADDRESS: STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC. STREET 2: 51 WEST 52ND STREET CITY: NEW YORK STATE: NY ZIP: 10019 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-07-14 0 0000722830 IMMUNOMEDICS INC IMMU 0001029578 GOLDENBERG DAVID M C/O IMMUNOMEDICS, INC. 300 AMERICAN ROAD MORRIS PLAINS NJ 07950 1 1 0 0 CSO & Chairman of the BOD Performance Rights 2015-07-14 4 A 0 1500000 0.00 A 2020-07-14 Common Stock, par value $0.01 per share 1500000 1500000 D Each performance right represents a contingent right to receive one share of Immunomedics, Inc. common stock. The performance rights will vest (i) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $7.35 or higher based on the average closing price for the prior 30 consecutive trading days; (ii) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $11.00 or higher based on the average closing price for the prior 30 consecutive trading days; and (iii) as to 500,000 shares (a) on or after the third anniversary of the grant date and (b) upon Immunomedics, Inc. common stock achieving a fair market value of $15.00 or higher based on the average closing price for the prior 30 consecutive trading days. /s/ David M. Goldenberg 2015-07-16